Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncopeptides AB ( (SE:ONCO) ) just unveiled an update.
Oncopeptides AB has announced a new share issue with preferential rights for existing shareholders, aiming to raise approximately SEK 150 million. The disclosure document for this rights issue has been registered with the Swedish Financial Supervisory Authority and is available on the company’s website. This move is part of the company’s strategy to strengthen its financial position and support its ongoing development of cancer therapies, potentially impacting its market presence and stakeholder interests.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides is a Swedish biotech company specializing in the research, development, and commercialization of targeted therapies for challenging cancer types. Utilizing its proprietary Peptide Drug Conjugate platform, the company develops compounds that effectively deliver cytotoxic agents to cancer cells. Oncopeptides’ flagship drug is being commercialized in Europe, with partnerships extending to South Korea, the Middle East, Africa, and other regions. Founded in 2000, the company operates in several European countries and is listed on Nasdaq Stockholm.
Average Trading Volume: 5,809,682
Technical Sentiment Signal: Buy
Current Market Cap: SEK931M
See more insights into ONCO stock on TipRanks’ Stock Analysis page.